🔍

INDGN - Indegene

📊 NSE: INDGN 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 7:57

📢 Recent Corporate Announcements

Indegene Limited to Meet Authum Investment on March 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:29 PM

Indegene Limited has scheduled a one-on-one in-person meeting with Authum Investment on March 18, 2026, in Bengaluru. This disclosure is made in compliance with SEBI Listing Obligations and Disclosure Requirements. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction. Such meetings are standard practice for maintaining investor relations and providing clarity on publicly available information.

One-on-one meeting scheduled with Authum Investment on March 18, 2026
The meeting will be conducted in-person at Bengaluru
Compliance filing under SEBI (LODR) Regulations, 2015
No unpublished price sensitive information (UPSI) to be shared during the meet

💡 No immediate action is required as this is a routine investor interaction. Investors should monitor the company's website for any new investor presentations that may be uploaded following the meeting.

Indegene CEO Manish Gupta Featured in Public Podcast on YouTube

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Mar 2026, 02:35 PM

Indegene Limited has filed a disclosure under Regulation 30 regarding a public podcast featuring its CEO, Manish Gupta. The podcast, titled 'The Indegene Story', is available on YouTube and provides insights into the company's journey. The company has explicitly stated that no unpublished price sensitive information (UPSI) was shared during the conversation. This filing is a routine regulatory compliance measure for management media appearances.

CEO Manish Gupta featured in a YouTube podcast titled 'The Indegene Story' released on March 12, 2026.
The disclosure was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Company confirms that no unpublished price sensitive information (UPSI) was disclosed during the session.

💡 Investors may watch the podcast to gain qualitative insights into the company's history and leadership vision, but no immediate financial impact is expected from this disclosure.

Indegene to Acquire Two UK Entities for GBP 2.7 Million in Internal Restructuring

🟡 NEUTRAL ⭐ 6/10

M&A 📅 01 Mar 2026, 05:33 PM

Indegene Limited is streamlining its corporate structure by acquiring 100% equity in two UK-based subsidiaries, DT Associates Research and Consulting Services and Trilogy Writing and Consulting, for a combined cash consideration of approximately GBP 2.7 million. This internal restructuring will bring both entities under Indegene Healthcare UK Limited. DT UK reported FY25 revenue of GBP 6.4 million, while Trilogy UK reported GBP 2.34 million. The transaction is expected to be completed by March 31, 2026, and is classified as a related party transaction conducted at arm's length.

Acquisition of 100% stake in DT UK for GBP 2,001,000 and Trilogy UK for GBP 702,348
DT UK revenue declined to GBP 6.4 million in FY25 from GBP 9.2 million in FY24
Trilogy UK showed revenue growth, reaching GBP 2.34 million for the period ending March 2025
The move is primarily for internal restructuring to consolidate UK-based life science service operations
Total cash consideration for both acquisitions is approximately GBP 2.703 million

💡 Investors should view this as a routine corporate cleanup to simplify the subsidiary hierarchy. No immediate impact on consolidated financials is expected as the entities were already part of the group.

Indegene Limited Schedules Investor Meetings with Locus Investment Group and Buoyant Capital

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 07:00 PM

Indegene Limited has announced a schedule for one-on-one meetings with institutional investors in March 2026. The company is set to meet Locus Investment Group virtually on March 2nd and Buoyant Capital in person on March 5th in Bengaluru. These meetings are part of the company's regular engagement with the investment community to discuss business operations. The company has clarified that no unpublished price sensitive information will be shared during these interactions.

Virtual 1x1 meeting scheduled with Locus Investment Group on March 2, 2026.
In-person 1x1 meeting scheduled with Buoyant Capital on March 5, 2026, in Bengaluru.
The interactions are part of routine investor relations and disclosure requirements under SEBI regulations.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed.

💡 No immediate action is required as these are routine investor meetings. Investors may look for any subsequent corporate presentations or transcripts if released by the company.

Indegene Limited Allots 327,880 Equity Shares Under ESOP and RSU Plans

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 09:09 PM

Indegene Limited has announced the allotment of 327,880 equity shares following a board resolution passed by circulation on February 20, 2026. The allotment includes shares issued under both the ESOP 2020 and RSU 2020 plans, covering categories with and without bonus elements. This action is part of the company's ongoing employee incentive and retention strategy. While this results in a marginal increase in the total paid-up capital, it is a standard procedure for growth-oriented tech-service firms.

Total allotment of 327,880 equity shares to eligible employees.
Shares issued under the ESOP 2020 and RSU 2020 incentive schemes.
Allotment covers plans both with and without bonus elements.
Resolution passed by the Board of Directors via circulation on February 20, 2026.

💡 No action is required as this is a routine administrative allotment. Investors should treat this as a standard part of employee compensation that causes minor equity dilution.

Indegene Limited Schedules Series of Investor Meetings with Major Mutual Funds in Feb 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Feb 2026, 04:51 PM

Indegene Limited has announced a comprehensive schedule for investor and analyst meetings spanning from February 19 to February 25, 2026. The company will engage in one-on-one meetings with prominent institutional investors including Nippon Mutual Fund, HDFC Mutual Fund, and HSBC Mutual Fund in Mumbai. Additionally, Indegene will participate in major industry events such as the IIFL 17th Entrepreneurial India Conference and Kotak's Chasing Growth 2026 conference. These meetings are intended to discuss business updates and strategy, though the company clarified that no unpublished price-sensitive information will be shared.

One-on-one meeting scheduled with DT Fund in Bangalore on February 19, 2026.
Multiple meetings with Nippon, HDFC, and HSBC Mutual Funds in Mumbai on February 23, 2026.
Participation in the IIFL 17th Entrepreneurial India Conference on February 24, 2026.
Attendance at the Kotak Institutional Equities: Chasing Growth 2026 conference on February 25, 2026.

💡 Investors should watch for any investor presentations or transcripts released following these meetings for insights into the company's growth trajectory. No immediate trading action is necessary as these are routine institutional interactions.

Indegene Schedules 1x1 Meetings with Fidelity, ICICI Pru, and Others on Feb 12-13

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 05:16 PM

Indegene Limited has announced a series of one-on-one meetings with prominent institutional investors scheduled for February 12 and 13, 2026. The company will engage with high-profile entities including Fidelity International, ICICI Prudential Mutual Fund, Abakkus Asset Manager, and ENAM Holdings. These in-person meetings in Mumbai are part of the company's regular investor relations outreach. While no unpublished price-sensitive information will be shared, the involvement of major funds indicates sustained institutional interest in the company.

Four one-on-one meetings scheduled with major institutional investors over a two-day period.
Meetings on February 12 include Abakkus Asset Manager, Fidelity International, and ENAM Holdings.
Meeting with ICICI Prudential Mutual Fund is scheduled for February 13, 2026.
All scheduled interactions are set to take place in person in Mumbai.

💡 No immediate action is required as these are routine investor meetings; however, investors should monitor for any new investor presentations uploaded to the exchanges.

Indegene Q3 FY26 Revenue Grows 30.8% YoY to INR 9,421 Mn; Large Deal Wins Boost Outlook

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 04 Feb 2026, 06:06 PM

Indegene reported a robust Q3 FY26 with total revenue of INR 9,421 million, a 30.8% YoY increase, including 18.3% organic growth. The company successfully integrated BioPharm and reported an adjusted EBITDA margin of 18.5%, with plans to reach 20% in 6-8 quarters. Significant deal wins were highlighted, including a $20 million TCV contract and a $10 million annual revenue engagement. Customer metrics improved with $1M+ accounts rising to 52 and revenue per employee exceeding $70,000.

Revenue increased 30.8% YoY to INR 9,421 million; organic growth was 18.3% YoY.
Adjusted EBITDA margin stood at 18.5%, up 30 bps QoQ despite acquisition-related costs.
Secured 7 large deals exceeding $1M ACV each, including a major $20M TCV biotech partnership.
$1M+ customer count grew by 12 to 52; active customers increased to 86.
Revenue per employee surpassed $70,000, driven by specialized AI-led platforms and domain expertise.

💡 Maintain a positive outlook given the strong deal pipeline and organic growth momentum. Watch for EBITDA margin expansion towards the 20% target as acquisition synergies and large deals scale.

Indegene Limited to Open Trading Window from February 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 07:15 PM

Indegene Limited has announced the opening of its trading window for designated persons starting February 1, 2026. This follows the completion of the approval and declaration process for the financial results for the quarter ended December 31, 2025. The notification is a standard compliance requirement under SEBI (Prohibition of Insider Trading) Regulations 2015. Designated persons and their immediate relatives are now permitted to trade in the company's equity shares until further notice.

Trading window for designated persons to officially open on February 1, 2026
Opening follows the declaration of financial results for the quarter ended December 31, 2025
Compliance maintained with SEBI Prohibition of Insider Trading Regulations 2015
Applies to all designated persons, their immediate relatives, and other insiders

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should focus on the actual financial performance reported for the December 2025 quarter.

Indegene Q3 Revenue Jumps 31% YoY to ₹9,421 Million; Completes ₹9,146 Million BioPharm Acquisition

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 07:02 PM

Indegene Limited reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for Q3 FY26. Net profit for the quarter stood at ₹1,029 million, showing stability despite the integration of the BioPharm acquisition which cost ₹9,146 million ($104 million). The company also announced the allotment of 13,332 equity shares under its RSU 2020 plan and reconstituted key board committees. The nine-month revenue for FY26 has reached ₹25,071 million, compared to ₹20,837 million in the previous year.

Revenue from operations grew 30.8% YoY to ₹9,421 million in Q3 FY26.
Completed acquisition of BioPharm Parent Holding Inc. for ₹9,146 million ($104 million) on October 1, 2025.
Consolidated net profit for the quarter recorded at ₹1,029 million with an EPS of ₹4.29.
Allotted 13,332 equity shares pursuant to the RSU 2020 Plan.
Nine-month total income reached ₹25,683 million, up from ₹21,653 million YoY.

💡 Investors should view the significant revenue growth and successful M&A integration as positive indicators of scale. Monitor the EBITDA margins in upcoming quarters to ensure the BioPharm acquisition is yielding the expected operational efficiencies.

Indegene Q3 FY26 Revenue Surges 30.8% YoY to ₹9,421 Mn; First $100M+ Revenue Quarter

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 06:49 PM

Indegene reported a strong Q3 FY26 with revenue growing 30.8% YoY to ₹9,421 million, marking its first quarter exceeding $100 million in revenue. While adjusted EBITDA grew 15.7% YoY to ₹1,747 million, reported PAT remained relatively flat at ₹1,026 million due to one-time acquisition costs and higher non-cash amortization. The company successfully completed the acquisitions of BioPharm (US) and Warn & Co. (UK), which contributed to the growth in the Enterprise Commercial Solutions segment. Management highlighted record productivity with revenue per employee crossing the $70,000 annual mark, driven by AI integration.

Revenue from operations grew 30.8% YoY to ₹9,421 million ($106.1 million).
Adjusted EBITDA rose 15.7% YoY to ₹1,747 million, though margins compressed slightly to 18.5%.
Active client base expanded to 86, with 52 clients now contributing over $1 million in annual revenue.
Cash and investments remain strong at ₹13,954 million even after acquisition-related outflows.
Revenue per employee reached an industry-leading $70,000+ annually due to AI-led productivity gains.

💡 Investors should look past the transient PAT flatness caused by acquisition accounting and focus on the robust 30%+ top-line growth and increasing client mining. The company's ability to scale revenue per employee through AI suggests significant long-term operating leverage.

Indegene Q3 FY26: Revenue Surges 30.8% YoY, Crosses $100M Quarterly Milestone

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 06:40 PM

Indegene reported a strong Q3 FY26 with revenue reaching INR 9,421 million, a 30.8% YoY and 17.1% QoQ increase, marking its first-ever $100 million+ revenue quarter. While Adjusted EBITDA grew 15.7% YoY to INR 1,747 million, Profit After Tax (PAT) remained flat at INR 1,026 million due to one-time acquisition costs and higher non-cash amortization. The company achieved an industry-leading revenue per employee of over $70,000 and successfully integrated two acquisitions, BioPharm and Warn & Co. Strong deal momentum continues with multiple new contracts exceeding $10 million in annual contract value.

Revenue from operations grew 30.8% YoY to INR 9,421 million ($106.1 million).
Adjusted EBITDA stood at INR 1,747 million with margins expanding 30bps sequentially to 18.5%.
Revenue per employee (RPE) crossed $70,000, the highest in the industry according to management.
Significant deal wins including two contracts exceeding $10 million ACV and one $20 million TCV contract.
Completed strategic acquisitions of BioPharm (US) and Warn & Co. (UK) to expand high-value capabilities.

💡 Investors should view the strong top-line growth and productivity metrics as a sign of competitive strength, while looking past the temporary PAT stagnation caused by acquisition-related accounting. Monitor the integration of new acquisitions for margin recovery in the coming quarters.

Indegene Q3 FY26 Revenue Grows 30.8% YoY to ₹9,421 Mn; PAT at ₹1,029 Mn

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 06:35 PM

Indegene reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for the quarter ended December 31, 2025. While revenue grew 17% sequentially, Profit After Tax (PAT) remained relatively flat at ₹1,029 million compared to the previous quarter, and slightly down from ₹1,097 million in the year-ago period due to higher tax expenses and depreciation. A significant highlight is the consolidation of BioPharm Parent Holding Inc., acquired for ₹9,146 million, which is expected to bolster the company's digital marketing and AI capabilities. The nine-month performance shows a healthy 20.3% revenue growth and an 11.2% increase in PAT.

Revenue from operations surged 30.8% YoY to ₹9,421 million in Q3 FY26.
Consolidated PAT for the quarter stood at ₹1,029 million, with 9M PAT rising 11.2% YoY to ₹3,214 million.
Completed the acquisition of BioPharm Parent Holding Inc. for ₹9,146 million (USD 104 million) on October 1, 2025.
Total expenses increased to ₹8,268 million, driven by higher employee benefits and depreciation following the acquisition.
Basic EPS for the quarter was ₹4.29, compared to ₹4.59 in the same quarter last year.

💡 Investors should monitor the successful integration of the BioPharm acquisition and its impact on margins in the coming quarters. The strong top-line growth suggests robust demand for digital-led life sciences services, making it a positive watch for long-term growth.

Indegene Appoints Jill DeSimone and Neeraj Bharadwaj to Board of Directors

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 12:06 PM

Indegene Limited has strengthened its Board of Directors with the appointment of Jill DeSimone and Neeraj Bharadwaj. DeSimone is a veteran in the life sciences industry with over 40 years of experience, notably leading the launch of the blockbuster drug Keytruda at Merck. Bharadwaj, a Senior Advisor at Carlyle Asia, brings extensive expertise in private equity, capital allocation, and inorganic growth. These appointments are aimed at enhancing corporate governance and providing strategic oversight as Indegene scales its technology-led commercialization services for global biopharma companies.

Jill DeSimone brings 40+ years of life sciences leadership, including her role as President of U.S. Oncology at Merck.
Neeraj Bharadwaj, a Senior Advisor at Carlyle Asia, joins with deep expertise in private equity and capital allocation.
DeSimone led the successful global launch of Keytruda, Merck's flagship oncology product.
The appointments focus on strengthening governance and supporting Indegene's technology-led modernization of life sciences.

💡 The addition of high-caliber global leaders to the board is a positive signal regarding Indegene's commitment to governance and global expansion. Investors should view this as a strengthening of the company's strategic leadership and long-term value creation potential.

Indegene Shareholders Approve Appointment of Neeraj Bharadwaj as Independent Director

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 23 Jan 2026, 11:07 PM

Indegene Limited has successfully passed a special resolution via postal ballot for the appointment of Mr. Neeraj Bharadwaj as an Independent Director. The voting process, which concluded on January 23, 2026, saw a total of 186.5 million votes polled, representing approximately 77.62% of the total shareholding. The resolution received overwhelming support, with 99.61% of the votes cast in favor of the appointment. This appointment strengthens the company's board governance and independent oversight.

Special resolution passed for the appointment of Mr. Neeraj Bharadwaj as an Independent Director
Total votes polled reached 186,538,018, accounting for 77.62% of outstanding shares
Resolution approved with a significant majority of 99.61% (185,805,074 votes) in favor
Only 0.39% of the votes (732,944) were cast against the resolution
The voting rights were determined based on the cut-off date of December 12, 2025

💡 This is a routine governance update that strengthens the board; investors should maintain their current outlook on the company as this does not change fundamental operations.

View All INDGN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Enterprise Commercial Solutions (60.6% of revenue) grew 26.2% YoY; Enterprise Medical Solutions (27.9% of revenue) grew 13.4% YoY; Brand Activation (7.9% of revenue) declined 20.0% YoY; Others (3.6% of revenue) grew 24.7% YoY.

Geographic Revenue Split

Over 96% of total revenue is generated from international markets, primarily North America and Europe.

Profitability Margins

PAT margin for FY 2024-25 was 14.3% (up from 13.0% in FY 2023-24). Q2 FY26 PAT margin was 12.7%, reflecting a 2.6% sequential reduction due to increased operational investments.

EBITDA Margin

Q2 FY26 EBITDA margin was 17.6%, down from 18.4% YoY and 20.2% in Q1 FY26. Management anticipates a near-term compression of 1.5% due to M&A and talent investments.

Capital Expenditure

Depreciation and amortization for FY 2024-25 was INR 80.2 Cr. Specific future Capex in INR Cr was not disclosed, though the company is investing heavily in talent and technology infrastructure.

Credit Rating & Borrowing

Finance costs for Q2 FY26 were INR 3.8 Cr, a 4.3% YoY decrease. Interest income fell 22.5% YoY to INR 18.4 Cr due to lower yields on investments in the US and India.

⚙️ Operational Drivers

Raw Materials

As a digital-first service provider, the primary 'raw material' is human capital. Employee benefit expenses represent 64.1% of total revenue (INR 515.8 Cr in Q2 FY26).

Import Sources

Talent is sourced globally, with major operational hubs in India, the United States, and the United Kingdom.

Key Suppliers

Not applicable for a service-based digital company; however, the company relies on technology vendors for its digital-first operating model.

Capacity Expansion

The company is investing in talent 'ahead of the curve' to support a growing deal pipeline. It recently acquired BioPharm (US) and WARN & Co. (UK) in October 2025 to expand consulting and medical capabilities.

Raw Material Costs

Employee benefit expenses grew 16.7% YoY to INR 515.8 Cr in Q2 FY26, driven by headcount increases and wage hikes implemented post-June.

Manufacturing Efficiency

Efficiency is measured by revenue per employee, which management describes as 'market leading' due to high-value digital service delivery.

📈 Strategic Growth

Expected Growth Rate

17.10%

Growth Strategy

Growth is driven by a 9-14% CAGR in the life sciences outsourcing market. Strategy includes scaling the Enterprise Commercial segment (26.2% YoY growth), integrating AI into healthcare delivery, and executing M&A like BioPharm and WARN & Co. to accelerate growth over 6-8 quarters.

Products & Services

Omnichannel commercialization services, medical affairs solutions, regulatory consulting, and digital marketing for life sciences companies.

Brand Portfolio

Indegene, BioPharm, WARN & Co.

New Products/Services

AI-integrated commercialization platforms and advanced transformation consulting services via the WARN & Co. acquisition.

Market Expansion

Focusing on mid-sized pharmaceutical companies beyond the top 20 global biopharma and expanding presence in the UK and US markets.

Market Share & Ranking

Ranked 432nd among the top 500 listed entities in India based on average market capitalization in its first year of listing.

Strategic Alliances

Acquired BioPharm (US-based boutique firm) and WARN & Co. (UK-based consulting firm) in October 2025.

🌍 External Factors

Industry Trends

Increasing digital and tech adoption in pharma; outsourcing operations across verticals are expected to grow at a 9-14% CAGR through 2026.

Competitive Landscape

Competes with global consulting firms and specialized life sciences service providers in a highly regulated market.

Competitive Moat

Durable advantage through deep healthcare domain expertise and a digital-first operating model that is difficult for generic IT firms to replicate.

Macro Economic Sensitivity

Sensitive to global interest rates; interest income declined 22.5% due to reducing Fed and repo rates affecting investment yields.

Consumer Behavior

Shift toward omnichannel and digital engagement by pharma companies to reach healthcare providers more efficiently.

Geopolitical Risks

US administration actions on drug pricing and potential tariff announcements create policy uncertainty for the biopharma industry.

⚖️ Regulatory & Governance

Industry Regulations

Operations are impacted by US healthcare regulations (IRA, MFN negotiations) and global pharmaceutical compliance standards for medical and commercial data.